What's Happening

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the treatment of hypertension to lower blood pressure

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

Indicated for topical treatment of plaque psoriasis

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Indicated for the treatment of partial-onset seizures.

A biosimilar to Rituxan^® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

A steroid-free topical indicated for treatment of plaque psoriasis

Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder

A first-time generic for Vimpat, this drug treats partial onset seizures

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.